Rohan Palekar
Chief Executive Officer chez 89BIO, INC.
Fortune : 5 M $ au 31/03/2024
Profil
Rohan Palekar is currently the Chief Executive Officer of Xenerex Biosciences, Chairman of Aim High For High School, Chief Executive Officer & Director of 89bio, Inc., and an Independent Director of Neurogene, Inc. In the past, he was the President & Chief Executive Officer of Avanir Pharmaceuticals, Inc., Vice President-Dermatology Sales & Marketing of Centocor, Inc., and Chief Commercial Officer of Medivation LLC (California).
He also served as an Independent Director of Neoleukin Therapeutics, Inc. Palekar received his undergraduate and graduate degrees from the University of Mumbai and his MBA from the Tuck School of Business at Dartmouth.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
89BIO INC
0,49% | 01/04/2024 | 459 171 ( 0,49% ) | 5 M $ | 31/03/2024 |
Postes actifs de Rohan Palekar
| Sociétés | Poste | Début |
|---|---|---|
| 89BIO, INC. | Chief Executive Officer | 01/06/2018 |
Xenerex Biosciences
 Xenerex Biosciences Miscellaneous Commercial ServicesCommercial Services Xenerex Biosciences engages in developing and commercializing human antibody products to target antigens. The company was founded by John David Hansen and Wolfgang W. Scholz and is headquartered in Aliso Viejo, CA. | Chief Executive Officer | - |
| Aim High For High School | Chairman | - |
Anciens postes connus de Rohan Palekar
| Sociétés | Poste | Fin |
|---|---|---|
| AVANIR PHARMACEUTICALS INC | Chief Executive Officer | 31/12/2017 |
| MEDIVATION INC | Corporate Officer/Principal | 09/09/2011 |
Centocor, Inc.
 Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | Sales & Marketing | 01/12/2007 |
| NEUROGENE INC. | Director/Board Member | - |
Formation de Rohan Palekar
| University of Mumbai | Graduate Degree |
| Tuck School of Business at Dartmouth | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| 89BIO, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Centocor, Inc.
Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | Health Technology |
Avanir Pharmaceuticals, Inc.
 Avanir Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Avanir Pharmaceuticals, Inc. engages in the development of therapeutic products for the treatment of nervous system disorder. The company was founded on August 31, 1988 and headquartered in Aliso Viejo, CA. | Health Technology |
Medivation LLC (California)
 Medivation LLC (California) Pharmaceuticals: MajorHealth Technology Medivation LLC engages in the development and commercialization of novel therapies to treat serious diseases for which there are limited treatment options. The company was founded by Clarence Patrick Machado and David T. Hung in 2004 and is headquartered in San Francisco, CA. | Health Technology |
Xenerex Biosciences
Xenerex Biosciences Miscellaneous Commercial ServicesCommercial Services Xenerex Biosciences engages in developing and commercializing human antibody products to target antigens. The company was founded by John David Hansen and Wolfgang W. Scholz and is headquartered in Aliso Viejo, CA. | Commercial Services |
Neoleukin Therapeutics, Inc.
 Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA. | Health Technology |
| Aim High For High School |
